Experimental pancreatic cancer vaccine shows promise in clinical trial

The article reports on a phase 2 trial of camupepimut, an experimental “off-the-shelf” pancreatic cancer vaccine targeting KRAS mutations. It triggered immune responses in nearly 99% of vaccinated patients but did not produce a statistically significant improvement in disease-free survival.